Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Stein

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Investigational New Drugs|March 23, 2011
A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumorsKyle Holen, Robert DiPaola, Glenn Liu, et al.
Investigational New Drugs|April 19, 2017
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumorsJanice M Mehnert, Gerald Edelman, Mark Stein, et al.
Anti-Cancer Drugs|December 16, 2016
Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomasSandrine Aspeslagh, Mark Stein, Rastilav Bahleda, et al.
Journal of Pediatric Psychology|September 16, 2024
Modernizing behavioral parent training program for ADHD with mHealth strategies, telehealth groups, and health behavior curriculum: a randomized pilot trialPooja S Tandon, Tess Gabert, Michelle Kuhn, et al.
Journal of Clinical Immunology|June 22, 2016
Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency DiseaseRichard L Wasserman, William Lumry, James Harris, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|March 22, 2003
ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label studyTimothy Wilens, William Pelham, Mark Stein, et al.
Journal of Clinical Immunology|September 7, 2017
Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials"Daniel Suez, Mark Stein, Sudhir Gupta, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|October 20, 2010
Effect of dopamine transporter genotype on caudate volume in childhood ADHD and controlsDevon Shook, Colin Brady, Philip S Lee, et al.
Journal of Clinical Immunology|September 2, 2016
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North AmericaDaniel Suez, Mark Stein, Sudhir Gupta, et al.
Immunotherapy|July 4, 2019
Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continentsDaniel Suez, Gergely Kriván, Stephen Jolles, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Investigational New Drugs|March 23, 2011
A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumorsKyle Holen, Robert DiPaola, Glenn Liu, et al.
Investigational New Drugs|April 19, 2017
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumorsJanice M Mehnert, Gerald Edelman, Mark Stein, et al.
Anti-Cancer Drugs|December 16, 2016
Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomasSandrine Aspeslagh, Mark Stein, Rastilav Bahleda, et al.
Journal of Pediatric Psychology|September 16, 2024
Modernizing behavioral parent training program for ADHD with mHealth strategies, telehealth groups, and health behavior curriculum: a randomized pilot trialPooja S Tandon, Tess Gabert, Michelle Kuhn, et al.
Journal of Clinical Immunology|June 22, 2016
Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency DiseaseRichard L Wasserman, William Lumry, James Harris, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|March 22, 2003
ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label studyTimothy Wilens, William Pelham, Mark Stein, et al.
Journal of Clinical Immunology|September 7, 2017
Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials"Daniel Suez, Mark Stein, Sudhir Gupta, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|October 20, 2010
Effect of dopamine transporter genotype on caudate volume in childhood ADHD and controlsDevon Shook, Colin Brady, Philip S Lee, et al.
Journal of Clinical Immunology|September 2, 2016
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North AmericaDaniel Suez, Mark Stein, Sudhir Gupta, et al.
Immunotherapy|July 4, 2019
Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continentsDaniel Suez, Gergely Kriván, Stephen Jolles, et al.
Pageof 7